

# Contents

<b>1</b>	<b>PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics . . .</b>	<b>1</b>
	Sameer S. Chopra and Lewis C. Cantley	

## Part I PI3K-mTOR Pathway in Cancers

<b>2</b>	<b>The mTOR Complexes in Cancer Cell Metabolism . . . . .</b>	<b>29</b>
	Thomas Lynch, Joseph G. Moloughney and Estela Jacinto	
<b>3</b>	<b>PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond . . . . .</b>	<b>65</b>
	Pradip De, Jennifer H. Carlson, Brian Leyland-Jones and Nandini Dey	
<b>4</b>	<b>The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures . . . . .</b>	<b>109</b>
	John Conor Moran, Elisa Baldelli, Emanuel F. Petricoin and Mariaelena Pierobon	
<b>5</b>	<b>Resistance to PI3K Pathway Inhibition . . . . .</b>	<b>125</b>
	Payal D. Shah and Sarat Chandarlapaty	

## Part II PI3K-mTOR Pathway in Cancer Medicine

<b>6</b>	<b>Combination Therapies Targeting the PI3K/AKT/mTOR Pathways. . . . .</b>	<b>151</b>
	Aung Naing, Gordon B. Mills and Funda Meric-Bernstam	
<b>7</b>	<b>Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma . . . . .</b>	<b>181</b>
	Charles B. Goodwin and Rebecca J. Chan	
<b>8</b>	<b>HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies. . . . .</b>	<b>231</b>
	Nandini Dey, Brian Leyland-Jones and Pradip De	

**9 The PI3K-mTOR Pathway in Prostate Cancer: Biological  
Significance and Therapeutic Opportunities . . . . . 263**  
Jason Boyang Wu and Leland W.K. Chung

**Index . . . . . 291**

PI3K-mTOR in Cancer and Cancer Therapy

Dey, N.; De, P.; Leyland-Jones, B. (Eds.)

2016, XXIV, 294 p. 31 illus. in color., Hardcover

ISBN: 978-3-319-34209-2

A product of Humana Press